Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma

Key facts

Sponsor

National Cancer Institute (NCI)

Principal Investigator

Gary Croghan, M.D

Mayo Clinic

Intervention

carboplatin(drug)

Enrollment

36 target

Eligibility

18 years · All sexes

Timeline

2005

Study locations (1)

• Mayo Clinic, Rochester, Minnesota, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Uveal melanoma

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07364474
  Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
  Massachusetts General Hospital
• RECRUITINGPHASE3NCT07015190
  Neoadjuvant Darovasertib in Primary Uveal Melanoma
  IDEAYA Biosciences
• RECRUITINGPHASE2NCT07276386
  Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
  H. Lee Moffitt Cancer Center and Research Institute
• RECRUITINGPHASE1, PHASE2NCT06961357
  Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
  H. Lee Moffitt Cancer Center and Research Institute
• RECRUITINGPHASE1NCT07203391
  Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis
  St Vincent's Hospital, Sydney
• RECRUITINGPHASE1NCT07076550
  A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma
  Alpha-9 Oncology USA Inc.
• RECRUITINGNCT07421739
  Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects
  Aura Biosciences
• RECRUITINGPHASE1, PHASE2NCT06626516
  Tebentafusp-tebn With LDT in Metastatic UM
  Thomas Jefferson University

See all trials for Uveal melanoma →